Preclinical trials of a new radiopharmaceutical for the treatment of ovarian cancer have shown promising results, with tumor growth and mass significantly reduced after use. The new radiopharmaceutical, which is designed exclusively for ovarian malignancies that are resistant to existing treatment, can be made in 25 minutes at a cheap cost, resulting in higher efficiency than alternative procedures. The new findings were presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting.
Each year, more than 20,000 women are diagnosed with ovarian cancer, with almost 14,000 dying from the disease, according to the American Cancer Society. Patients with ovarian cancer have a five year survival rate of 49.1%. It is the seventh most common cause of cancer death in women.
The study’s researchers used a novel generator method to generate Pb-214-TCMC-trastuzumab, a targeted alpha-therapy for HER2-positive ovarian cancer. Ovarian cancer cells and mice with ovarian cancer tumors were divided into three groups: those who received Pb-214-TCMC-trastuzumab, those who received Pb-214-TCMC-IgG, and those who received no treatment. To assess the treatment’s efficacy, all groups were scanned over time.
The tumor signal for mice and cells treated with Pb-214-TCMC-trastuzumab reduced considerably during the course of the study as compared to the Pb-214-TCMC-IgG and control groups, indicating the therapy’s efficacy. The medication had no negative side effects, as indicated by the weight loss of all mice that survived.
“The short 27-minute half-life of Pb-214 is ideal for fractioned alpha particle therapeutic applications,” stated Mike Zamiara, study author and president of Niowave Inc. in East Lansing, Michigan. “The generator system can provide Pb-214 every hour, potentially providing a new source of alpha particle therapy to patients at lower cost. In the future, the generator system will be available for many therapeutic products in a turn-key system under development, providing reliable doses for improved patient care.”
Abstract 93. “Therapeutic Efficacy of Pb-214-labeled Trastuzumab in a Preclinical Model of Ovarian Cancer,” Abdullah Metebi, Comparative Medicine and Integrative Biology, Michigan State University, East Lansing, Michigan; Chelsea Nayback, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan; Jinda Fan, Departments of Radiology and Chemistry, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan; Nathan Johnson, John Diemer, Terry Grimm, Mike Zamiara, Niowave, Inc., Lansing, Michigan; and Kurt Zinn, Radiology and Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan.
All 2021 SNMMI Annual Meeting abstracts can be found online at https://jnm.snmjournals.org/content/62/supplement_1.